Retraction: Transactivation of the EGR1 gene contributes to mutant p53 gain of function (Cancer Res (2019) 64 (8318–8327) DOI: 10.1158/0008-5472.CAN-04-1145);Transactivation of the EGR1 gene contributes to mutant p53 gain of function

Cancer Research

Volumn 64, Issue 22, 2004, Pages 8318-8327

  Weisz, Lilach ^a   Zalcenstein, Amir ^a   Stambolsky, Perry ^a   Cohen, Yehudit ^a   Goldfinger, Naomi ^a   Oren, Moshe ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; MUTANT PROTEIN; PROTEIN P53; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CHROMATIN; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INDUCTION; STRESS; TRANSACTIVATION; UPREGULATION;

EID: 8544268687     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-19-0560     Document Type: Erratum

References (65)

1. Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001;277:15-30.
2. Janus F, Albrechtsen N, Dornreiter I, Wiesmuller L, Grosse F, Deppert W. The dual role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 1999;55:12-27.
3. Hussain SP, Harris CC. Molecular epidemiology of human cancer. Recent Results Cancer Res 1998;154:22-36.
4. Deppert W, Gohler T, Koga H, Kim E. Mutant p53: "gain of function" through perturbation of nuclear structure and function? J Cell Biochem Suppl 2000;(35):115-22.
5. Roemcr K. Mutant p53: Gain of function oncoproteins and wild-type p53 inactivators. Biol Chem 1999;380:879-87.
6. Halevy O, Michalovitz D, Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990;250:113-6.
7. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 1993;4:42-6.
8. Hsiao M, Low J, Dorn E, et al. Gain-of-function mutations of the p53 gene induce lymphhematopoietic metastatic potential and tissue invasiveness. Am J Pathol 1994;145:702-14.
9. Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyoizumi S, Seyama T. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation. independently of the cell cycle and cell survival. Cancer Res 1996;56:3862-5.
10. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
11. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85.
12. Li R, Sutphin PD, Schwartz D, et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998;16:3269-77.
13. Matas D, Sigal A, Stambolsky P, et al. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 2001;20:4163-72.
14. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 EIB 55-kD protein. Genes Dev 1994;8:1235-46.
15. Lin J, Teresky AK, Levine AJ. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 1995;10:2387-90.
16. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of C-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 1998;18:3735-43.
17. Margulies L, Sehgal PB. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPb (NF-IL6) activity by p53 species. J Biol Chem 1993;268:15096-100.
18. Tsutsumi-lshii Y, Todakoro K, Hanaoka F, Tsuchida N. Response of heat shock element within the human HSP70 promoter to mutated p53 genes. Cell Growth Differ 1995;6:1-8.
19. Ludes-Meyers JH, Subler MA, Shivakumar V, et al. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 1996;16:6009-19.
20. Subler MA, Martin DW, Deb S. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol 1994;68:103-10.
21. Deppert W. Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions. J Cell Biochem 1996;62:172-80.
22. Adamson ED, Mercola D. Egr1 transcription factor: multiple roles in prostate tumor cell growth and survival. Tumour Biol 2002;23:93-102.
23. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002;193:287-92.
24. Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 1999;450:197-204.
25. Quinones A, Dobberstein KU, Rainov NG. The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. Life Sci 2003;72:2975-92.
26. Yan SF, Fujita T, Lu J, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000;6:1355-61.
27. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-9.
28. Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003;31:693-701.
29. Zalcenstein A, Stambolsky P, Weisz L, et al. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 2003;22:5667-76.
30. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003;9:1026-32.
31. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997;16:750-9.
32. Yan SF, Pinsky DJ, Mackman N, Stern DM. Egr-1: is it always immediate and early? J Clin Investig 2000;105:553-4.
33. Kaufmann K, Thiel G. Epidermal growth factor and platelet-derived growth factor induce expression of Egr-1, a zinc finger transcription factor in human malignant glioma cells. J Neurol Sci 2001;189:83-91.
34. Kaufmann K, Thiel G. Epidermal growth factor and thrombin induced proliferation of immortalized human keratinocytes is coupled to the synthesis of Egr-1, a zinc finger transcriptional regulator. J Cell Biochem 2002;85:381-91.
35. Baron V, De Gregorio G, Krones-Herzig A, et al. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 2003;22:4194-204.
36. Nguyen HQ, Selvakumaran M, Liebermann DA, Hoffman B. Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells. Oncogene 1995;11:2439-44.
37. Huang RP, Liu C, Fan Y, Mercola D, Adamson ED. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res 1995;55:5054-62.
38. Virolle T, Adamson ED, Baron V, et al. The Egr-1 transcription factor direcily activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001;3:1124-8.
39. Virolle T, Krones-Herzig A, Baron V, Gregorio GG, Adamson ED, Mercola D. Egr1 promotes growth and survival of prostate cancer cells: identification of novel Egr1 target genes. J Biol Chem 2003;278:11802-10.
40. Bae SK, Bae MH, Ahn MY, et al. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res 1999;59:5989-94.
41. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 1996;271:1427-31.
42. Wang ZY, Madden SL, Deuel TF, Rauscher FJ III. The Wilms' tumor gene product, WTI, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 1992;267:21999-2002.
43. Cogswell PC, Mayo MW, Baldwin AS Jr. Involvement of Egr-1/RelA synergy in distinguishing T cell activation from tumor necrosis factor-α-induced NF-κ B1 transcription. J Exp Med 1997;185:491-7.
44. Huang RP, Fan Y, Peng A, et al. Suppression of human fibrosarcoma cell growth by transcription factor. Egr-1, involves down-regulation of Bcl-2, Int J Cancer 1998;77:880-6.
45. Liu C, Yao J, Mercola D, Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 2000;275:20315-23.
46. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM. Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 1997;272:20131-8.
47. Yao J, Mackman N, Edgington TS, Fan ST. Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells: regulation by Egr-1, c-Jun, and NF-κB transcription factors. J Biol Chem 1997;272:17795-801.
48. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-I. Blood 1999;93:3811-23.
49. Liu C, Adamson E, Mercola D. Transcription factor EGR-I suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor β 1. Proc Natl Acad Sci USA 1996;93:11831-6.
50. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA, Milbrandt J. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 2000;275:38524-31.
51. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. Expression of early growth response genes in human prostate cancer. Cancer Res 1998;58:2461-8.
52. Scharnhorst V, Menke AL, Attema J, et al. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene 2000;19:791-800.
53. Calogero A, Arcella A, De Gregorio G, et al. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res 2001;7:2788-96.
54. Huang RP, Fan Y, de Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 1997;72:102-9.
55. Levin WJ, Press MF, Gaynor RB, et al. Expression patterns of immediate early transcription factors in human non-small cell lung cancer: The Lung Cancer Study Group. Oncogene 1995;11:1261-9.
56. Liu C, Rangnekar VM, Adamson E, Mercola D. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 1998;5:3-28.
57. Abdulkadir SA, Qu Z, Garabedian E, et al. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 2001;7:101-7.
58. Gashler A, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol 1995;50:191-224.
59. Khachigian LM, Collins T. Inducible expression of Egr-1-dependent genes: a paradigm of transcriptional activation in vascular endothelium. Circ Res 1997;81:457-61.
60. Krones-Herzig A, Adamson E, Mercola D. Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci USA 2003;100:3233-8.
61. Sakaue M, Adachi H, Dawson M, Jetten AM. Induction of Egr-1 expression by the retinoid AHPN in human lung carcinoma cells is dependent on activated ERK1/2. Cell Death Differ 2001;8:411-24.
62. Pignatelli M, Luna-Medina R, Perez-Rendon A, Santos A, Perez-Castillo A. The transcription factor early growth response factor-1 (EGR-1) promotes apoptosis of neuroblastoma cells. Biochem J 2003;373:739-46.
63. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-4.
64. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438-49.
65. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-10.